Literature DB >> 17964019

Epidemiology of brain tumors.

James L Fisher1, Judith A Schwartzbaum, Margaret Wrensch, Joseph L Wiemels.   

Abstract

Brain tumors seemed to have increased in incidence over the past 30 years, but the rise probably results from use of new neuroimaging techniques. Treatments have not improved prognosis for rapidly fatal brain tumors. Established brain tumor risk factors (exposure to ionizing radiation, rare mutations of penetrant genes, and familial history) explain only a small proportion of brain tumors, and only one of these potentially is modifiable. Genetic and environmental characteristics likely play a role in familial aggregation of glioma and these factors are not identified. New concepts in brain tumor etiology and clinical management are the goal of research, with an aim at eradicating this devastating disease.

Entities:  

Mesh:

Year:  2007        PMID: 17964019     DOI: 10.1016/j.ncl.2007.07.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  126 in total

1.  Antihistamine use and immunoglobulin E levels in glioma risk and prognosis.

Authors:  E Susan Amirian; Deborah Marquez-Do; Melissa L Bondy; Michael E Scheurer
Journal:  Cancer Epidemiol       Date:  2013-08-30       Impact factor: 2.984

2.  Glioblastoma in a former Chernobyl resident 24 years later.

Authors:  Adam A Dmytriw; Gwynedd E Pickett
Journal:  CMAJ       Date:  2013-07-02       Impact factor: 8.262

3.  Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging.

Authors:  Boguslaw Tomanek; Umar Iqbal; Barbara Blasiak; Abedelnasser Abulrob; Homam Albaghdadi; John R Matyas; Dragana Ponjevic; Garnette R Sutherland
Journal:  Neuro Oncol       Date:  2011-10-19       Impact factor: 12.300

4.  Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma.

Authors:  Bin Wang; Ming Li; Zhonghua Wu; Xiqing Li; Y U Li; Xiwen Shi; Wenlan Cheng
Journal:  Exp Ther Med       Date:  2015-05-12       Impact factor: 2.447

5.  Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Authors:  Carmen Balañá; Olatz Etxaniz; Cristina Bugés; Alex Martínez
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

Review 6.  NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.

Authors:  G Kenneth Gray; Braden C McFarland; Susan E Nozell; Etty N Benveniste
Journal:  Expert Rev Neurother       Date:  2014-09-29       Impact factor: 4.618

7.  Cancers of the brain and CNS: global patterns and trends in incidence.

Authors:  Adalberto Miranda-Filho; Marion Piñeros; Isabelle Soerjomataram; Isabelle Deltour; Freddie Bray
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

Review 8.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

Review 9.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

10.  Incidence of first primary central nervous system tumors in California, 2001-2005.

Authors:  Monica Brown; Rudolph Schrot; Katrina Bauer; Deanna Letendre
Journal:  J Neurooncol       Date:  2009-04-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.